PT1931315E - Formulações de libertação sustentada de nalbufina - Google Patents
Formulações de libertação sustentada de nalbufina Download PDFInfo
- Publication number
- PT1931315E PT1931315E PT67899641T PT06789964T PT1931315E PT 1931315 E PT1931315 E PT 1931315E PT 67899641 T PT67899641 T PT 67899641T PT 06789964 T PT06789964 T PT 06789964T PT 1931315 E PT1931315 E PT 1931315E
- Authority
- PT
- Portugal
- Prior art keywords
- nalbuphine
- sustained release
- release formulations
- formulations
- sustained
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71077205P | 2005-08-24 | 2005-08-24 | |
US77246606P | 2006-02-10 | 2006-02-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1931315E true PT1931315E (pt) | 2014-01-03 |
Family
ID=37772363
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT111789129T PT2402005T (pt) | 2005-08-24 | 2006-08-24 | Formulações de libertação sustentada de nalbufina |
PT67899641T PT1931315E (pt) | 2005-08-24 | 2006-08-24 | Formulações de libertação sustentada de nalbufina |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT111789129T PT2402005T (pt) | 2005-08-24 | 2006-08-24 | Formulações de libertação sustentada de nalbufina |
Country Status (10)
Country | Link |
---|---|
US (2) | US8771732B2 (pt) |
EP (2) | EP1931315B1 (pt) |
JP (1) | JP2009506059A (pt) |
CA (2) | CA2881739C (pt) |
DK (2) | DK2402005T3 (pt) |
ES (2) | ES2441766T3 (pt) |
HU (1) | HUE053838T2 (pt) |
PL (2) | PL1931315T3 (pt) |
PT (2) | PT2402005T (pt) |
WO (1) | WO2007025005A2 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003004030A1 (en) | 2001-07-06 | 2003-01-16 | Endo Pharmaceuticals, Inc. | Oxymorphone controlled release formulations |
TWI319713B (en) * | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
US8487002B2 (en) * | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
ES2389666T3 (es) * | 2005-09-09 | 2012-10-30 | Angelini Labopharm, Llc | Composición de trazodona para una administración de una vez al día |
MX336494B (es) * | 2007-10-16 | 2016-01-21 | Paladin Labs Inc | Composicion de bicapas para la liberacion controlada de acetaminofeno y tramadol. |
KR20100121463A (ko) | 2007-12-17 | 2010-11-17 | 라보팜 인코포레이트 | 오용 예방적 방출 제어형 제제 |
JP2011530529A (ja) * | 2008-08-07 | 2011-12-22 | アバントール パフォーマンス マテリアルズ, インコーポレイテッド | ゴムおよび糖アルコールを含む徐放性組成物 |
ES2509497T3 (es) * | 2008-12-16 | 2014-10-17 | Paladin Labs Inc. | Formulación de liberación controlada para evitar un uso indebido |
FR2949061B1 (fr) * | 2009-08-12 | 2013-04-19 | Debregeas Et Associes Pharma | Microgranules flottants |
FR2963889B1 (fr) * | 2010-08-20 | 2013-04-12 | Debregeas Et Associes Pharma | Formulations a base de nalbuphine et leurs utilisations |
ES2829223T3 (es) | 2011-04-29 | 2021-05-31 | Univ Rutgers | Método de tratamiento de la discinesia |
US10736889B2 (en) | 2011-04-29 | 2020-08-11 | Rutgers, The State University Of New Jersey | Method of treating dyskinesia |
US9918980B2 (en) | 2011-04-29 | 2018-03-20 | Rutgers, The State University Of New Jersey | Method of treating dyskinesia |
MX2015007518A (es) * | 2012-12-14 | 2016-03-01 | Trevi Therapeutics Inc | Metodos para tratar el prurito. |
US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
US8637538B1 (en) * | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
WO2015192071A1 (en) * | 2014-06-13 | 2015-12-17 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
JP2017100971A (ja) * | 2015-11-30 | 2017-06-08 | 株式会社ファンケル | 錠剤 |
CN105560202B (zh) * | 2016-03-11 | 2019-05-24 | 广州玻思韬控释药业有限公司 | 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用 |
CN112703000B (zh) | 2018-07-23 | 2024-05-31 | 特雷维治疗股份有限公司 | 慢性咳嗽、呼吸急促和呼吸困难的治疗 |
US20240131022A1 (en) * | 2022-03-11 | 2024-04-25 | John Abernethy | Opioid overdose reversal mixtures |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4237140A (en) * | 1979-05-18 | 1980-12-02 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and acetaminophen |
US4282215A (en) * | 1980-06-17 | 1981-08-04 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof |
US4404211A (en) * | 1982-06-30 | 1983-09-13 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and flurbiprofen |
US4407805A (en) * | 1982-06-30 | 1983-10-04 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and zomepirac |
US4407804A (en) * | 1982-06-30 | 1983-10-04 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and indomethacin |
US4404208A (en) * | 1982-06-30 | 1983-09-13 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and tiflamizole |
US4404209A (en) * | 1982-06-30 | 1983-09-13 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and sulindac |
US4404210A (en) * | 1982-06-30 | 1983-09-13 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and ibuprofen |
US4402962A (en) * | 1982-06-30 | 1983-09-06 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and 4,5-bis(4-methoxyphenyl)-2-(trifluoromethylsulfonyl)-1H-imidazole |
IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US4720384A (en) * | 1985-05-03 | 1988-01-19 | E. I. Du Pont De Nemours And Company | Manufacture of hollow fine tubular drug delivery systems |
US5028612A (en) * | 1990-03-22 | 1991-07-02 | Hillel Glover | Method for treating emotional numbness |
US5013740A (en) * | 1990-03-22 | 1991-05-07 | Hillel Glover | Method for treating emotional numbness and coma |
US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
DE69427551T2 (de) | 1993-03-15 | 2002-05-16 | National Science Council, Taipeh/T'ai-Pei | Nalbuphinester und diese enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe |
US5399358A (en) * | 1993-11-12 | 1995-03-21 | Edward Mendell Co., Inc. | Sustained release formulations for 24 hour release of metroprolol |
US5750534A (en) * | 1994-03-16 | 1998-05-12 | National Science Council | Nalbuphine esters having long acting analgesic action and method of use |
US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US20030211157A1 (en) * | 1996-05-06 | 2003-11-13 | Simon David Lew | Semi-sol delivery blend for water soluble molecules |
US5948787A (en) * | 1997-02-28 | 1999-09-07 | Alza Corporation | Compositions containing opiate analgesics |
US6225321B1 (en) * | 1997-06-05 | 2001-05-01 | Oliver Yoa-Pu Hu | Long analgesic acting nalbuphine polyester derivative and method of use |
US6372254B1 (en) * | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
US6602521B1 (en) * | 1998-09-29 | 2003-08-05 | Impax Pharmaceuticals, Inc. | Multiplex drug delivery system suitable for oral administration |
US6806294B2 (en) * | 1998-10-15 | 2004-10-19 | Euro-Celtique S.A. | Opioid analgesic |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
BR0013825A (pt) * | 1999-08-31 | 2002-07-23 | Gruenenthal Chemie | Formas de apresentação de tramadol |
JP2003508420A (ja) * | 1999-09-02 | 2003-03-04 | ノストラム・ファーマスーティカルズ・インコーポレイテッド | 経口投与に適した、制御された放出の経口用量 |
US6475493B1 (en) * | 1999-09-02 | 2002-11-05 | Norstrum Pharmaceuticals, Inc. | Controlled release pellet formulation |
DE60038536T2 (de) | 1999-09-30 | 2009-06-10 | Penwest Pharmaceuticals Co. | Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe |
EP1149836B1 (en) | 2000-04-27 | 2003-02-26 | Oliver Yoa-Pu Hu | Polynalbuphine derivatives |
EP1292307A2 (en) | 2000-06-09 | 2003-03-19 | The Regents of The University of California | Method of treating pain using nalbuphine and opioid antagonists |
US6692771B2 (en) * | 2001-02-23 | 2004-02-17 | Cima Labs Inc. | Emulsions as solid dosage forms for oral administration |
US20050176790A1 (en) * | 2001-02-28 | 2005-08-11 | Johannes Bartholomaus | Pharmaceutical salts |
AU2002314968B2 (en) * | 2001-06-08 | 2006-12-07 | Endo Pharmaceuticals, Inc. | Controlled release dosage forms using acrylic polymer, and process for making the same |
US6703398B2 (en) | 2001-11-26 | 2004-03-09 | Oliver Yoa-Pu Hu | Orally administered analgesic compositions containing nalbuphine |
JP2005537298A (ja) | 2002-08-02 | 2005-12-08 | ペンウェスト ファーマシューティカルズ カンパニー | メトホルミンの徐放性製剤 |
SI2218448T1 (sl) * | 2002-12-13 | 2016-01-29 | Durect Corporation | Sistem za oralno dajanje zdravila, ki obsega tekoči nosilec materialov z visoko viskoznostjo |
CA2510465A1 (en) * | 2002-12-18 | 2004-07-08 | Pain Therapeutics | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
JP2006520392A (ja) * | 2003-03-13 | 2006-09-07 | コントロールド・ケミカルズ・インコーポレーテッド | 薬物の乱用可能性を低下させ且つ作用持続時間を延長する化合物および方法 |
US20050074493A1 (en) * | 2003-10-03 | 2005-04-07 | Mehta Atul M. | Extended release formulations of opioids and method of use thereof |
US20050165038A1 (en) * | 2004-01-22 | 2005-07-28 | Maxwell Gordon | Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects |
EP1584335A3 (en) * | 2004-04-05 | 2006-02-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising a carbinol composition and an opioid |
US20060111382A1 (en) * | 2004-05-17 | 2006-05-25 | Pharmacofore, Inc. | Compositions and methods for treating or preventing pain |
-
2006
- 2006-08-24 ES ES06789964.1T patent/ES2441766T3/es active Active
- 2006-08-24 EP EP06789964.1A patent/EP1931315B1/en active Active
- 2006-08-24 HU HUE11178912A patent/HUE053838T2/hu unknown
- 2006-08-24 CA CA2881739A patent/CA2881739C/en active Active
- 2006-08-24 US US11/509,347 patent/US8771732B2/en active Active
- 2006-08-24 CA CA2620224A patent/CA2620224C/en active Active
- 2006-08-24 DK DK11178912.9T patent/DK2402005T3/da active
- 2006-08-24 DK DK06789964.1T patent/DK1931315T3/da active
- 2006-08-24 PL PL06789964T patent/PL1931315T3/pl unknown
- 2006-08-24 EP EP11178912.9A patent/EP2402005B1/en active Active
- 2006-08-24 PT PT111789129T patent/PT2402005T/pt unknown
- 2006-08-24 WO PCT/US2006/033011 patent/WO2007025005A2/en active Application Filing
- 2006-08-24 ES ES11178912T patent/ES2862573T3/es active Active
- 2006-08-24 PT PT67899641T patent/PT1931315E/pt unknown
- 2006-08-24 JP JP2008528135A patent/JP2009506059A/ja active Pending
- 2006-08-24 PL PL11178912T patent/PL2402005T3/pl unknown
-
2014
- 2014-06-30 US US14/319,833 patent/US9186330B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2402005A1 (en) | 2012-01-04 |
WO2007025005A3 (en) | 2007-12-21 |
US8771732B2 (en) | 2014-07-08 |
CA2881739A1 (en) | 2007-03-01 |
JP2009506059A (ja) | 2009-02-12 |
PT2402005T (pt) | 2021-04-14 |
EP1931315A2 (en) | 2008-06-18 |
ES2441766T3 (es) | 2014-02-06 |
CA2881739C (en) | 2018-01-02 |
WO2007025005A2 (en) | 2007-03-01 |
ES2862573T3 (es) | 2021-10-07 |
EP2402005B1 (en) | 2020-12-16 |
EP1931315B1 (en) | 2013-10-16 |
US20140315937A1 (en) | 2014-10-23 |
DK1931315T3 (da) | 2014-01-20 |
US20070048376A1 (en) | 2007-03-01 |
HUE053838T2 (hu) | 2021-07-28 |
PL2402005T3 (pl) | 2021-11-22 |
PL1931315T3 (pl) | 2014-09-30 |
CA2620224C (en) | 2015-11-24 |
CA2620224A1 (en) | 2007-03-01 |
DK2402005T3 (da) | 2021-03-15 |
US9186330B2 (en) | 2015-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2402005T3 (pl) | Formulacje nalbufiny o przedłużonym uwalnianiu | |
IL246026A0 (en) | Delayed release of anti-infectives | |
HK1200092A1 (en) | Sustained release formulations | |
IL184460A0 (en) | Sustained release pharmaeutical formulations | |
IL185800A0 (en) | Controlled release formulations of octreotide | |
IL184822A0 (en) | Extended release formulation of levetiracetam | |
EP1895991A4 (en) | MODIFIED RELEASE FORMULATIONS OF ANTI-IRRITABLE DRUGS | |
GB0406819D0 (en) | Controlled release compositions | |
IL188964A0 (en) | Sustained drug release composition | |
EP1883406A4 (en) | COMPOSITIONS AND METHOD FOR CONTINUOUS RELEASE OF BETA-ALLANINE | |
EP1765385A4 (en) | IMPORTS COMPOSITION WITH DELAYED RELEASE | |
EP1714643A4 (en) | PREPARATION WITH DELAYED RELEASE | |
SI1732548T2 (sl) | Postopki za uporabo aminopiridinskih sestavkov s podaljšanim sproščanjem | |
EP1802346A4 (en) | PHARMACEUTICAL COMPOSITION WITH EXTENDED RELEASE | |
EP1951693A4 (en) | SOLID FORMULATIONS | |
IL178383A0 (en) | Delayed release formulations of 6-mercaptopurine | |
IL190865A0 (en) | Formulations of quinolinones | |
ZA200705011B (en) | Formulations of substituted benzoxazoles | |
IL177328A0 (en) | Controlled release formulations | |
EP1871348A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE | |
IL198169A0 (en) | Robust sustained release formulations of oxymorphone | |
ZA200803213B (en) | Formulations of quinolinones | |
ZA200606408B (en) | Controlled release pharmaceutical compositions |